Floatz logo

N-Desmethyl-4-Hydroxytamoxifen

Bipolar I Disorder

Jina Pharmaceuticals Inc.Small moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

30 Active assets in the Bipolar I Disorder cohort.

Asset / SponsorPhaseRating
Lurasidone
Massachusetts General Hospital
Phase 4BBB
Lithium, Elemental
Alzamend Neuro, Inc.
Phase 4BBB
Escitalopram
Massachusetts General Hospital
Phase 4BBB
Olanzapine
Alkermes, Inc.
Phase 4BBB
Valproic Acid
Bristol-Myers Squibb
Phase 4BBB

View all 50 →

Same molecule, other indications

N-Desmethyl-4-Hydroxytamoxifen is also rated in:

angiosarcomaActive
CCC
Indicative · Phase 2
53 / 100
View asset →
ductal breast carcinoma in situActive
CCC
Indicative · Phase 2
53 / 100
View asset →
invasive breast carcinomaActive
CCC
Indicative · Phase 2
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →